Daré Bioscience Completes Regulation A Preferred Stock Offering

Daré Bioscience ( (DARE) ) has issued an announcement.

On April 17, 2026, Daré Bioscience, Inc. closed a previously announced Regulation A offering of Investor Units, each comprising one share of Series A Convertible Preferred Stock and two Investor Warrants, at an offering price of $5.00 per unit. In this closing, the company issued 20,000 Investor Units, representing 20,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 40,000 shares of common stock, modestly strengthening its capital position and providing additional potential equity through warrant exercises.

The offering was conducted under an offering statement on Form 1-A that was most recently qualified by the U.S. Securities and Exchange Commission on April 1, 2026, and supported by an offering circular and supplement dated January 6 and March 26, 2026, respectively. By completing this tranche of the Regulation A offering, Daré advanced its financing strategy to support ongoing corporate operations and development programs while signaling continued access to public capital markets.

The most recent analyst rating on (DARE) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Spark’s Take on DARE Stock

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

The score is primarily weighed down by weak financial performance driven by large losses, significant 2025 cash burn, and historically unstable equity, indicating high capital dependence. Technicals are a relative positive with strong momentum, but overbought signals raise near-term reversal risk. Valuation is constrained by negative earnings and no dividend support, while earnings-call updates and recent financings provide some operational runway but also reflect ongoing funding needs and potential dilution.

To see Spark’s full report on DARE stock, click here.

More about Daré Bioscience

Daré Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing products, including novel contraceptives and therapies, in the women’s health market. The company operates in the life sciences industry and accesses the capital markets to fund its research, development, and commercialization activities.

Average Trading Volume: 84,907

Technical Sentiment Signal: Hold

Current Market Cap: $26.06M

For detailed information about DARE stock, go to TipRanks’ Stock Analysis page.